113 related articles for article (PubMed ID: 6804290)
41. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
Wood DJ
Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
[TBL] [Abstract][Full Text] [Related]
42. An enzyme-linked immunosorbent assay, ELISA, for SV40 antigen detection.
Edevåg G; Grandien M; Mares I
J Virol Methods; 1985 Aug; 11(4):347-55. PubMed ID: 2997255
[TBL] [Abstract][Full Text] [Related]
43. Development of an enzyme-linked immunosorbent assay for the serological diagnosis of big liver and spleen disease.
Todd D; Mawhinney KA; McAlinden VA; Douglas AJ
Avian Dis; 1993; 37(3):811-6. PubMed ID: 8257376
[TBL] [Abstract][Full Text] [Related]
44. The durability of inactivated poliovirus vaccine: studies on the stability of potency in vivo and in vitro.
Moynihan M; Petersen I
J Biol Stand; 1982 Jul; 10(3):261-8. PubMed ID: 6813334
[No Abstract] [Full Text] [Related]
45. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
[TBL] [Abstract][Full Text] [Related]
46. [Microfilaria of Dirofilaria corynodes (Linstow, 1899) as a new contaminating agent of cell tissue cultures for the production of vaccine against poliomyelitis].
Furmaga S; Gundlach JL; Grzybek D; Woźniak M
Wiad Parazytol; 1971; 17(1):65-73. PubMed ID: 4997444
[No Abstract] [Full Text] [Related]
47. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
Furesz J
Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
[TBL] [Abstract][Full Text] [Related]
48. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
[TBL] [Abstract][Full Text] [Related]
49. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
50. Potency testing for killed poliomyelitis vaccine.
Beale AJ
Dev Biol Stand; 1981; 47():69-75. PubMed ID: 6262161
[No Abstract] [Full Text] [Related]
51. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
[TBL] [Abstract][Full Text] [Related]
52. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
53. Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.
Rezapkin GV; Alexander W; Dragunsky E; Parker M; Pomeroy K; Asher DM; Chumakov KM
Virology; 1998 Jun; 245(2):183-7. PubMed ID: 9636357
[TBL] [Abstract][Full Text] [Related]
54. [Effective inactivatian test of inactivated hepatitis A vaccine using integrated cell culture/strand-specific reverse transcriptase-polymerase chain reaction].
Zhou J; Ji G; Wen JN; Li J; Sheng W; Guo ZQ; Liao GY; Jiang SD; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):488-91. PubMed ID: 19544655
[TBL] [Abstract][Full Text] [Related]
55. Antibody responses against avian reovirus nonstructural protein sigmaNS in experimentally virus-infected chickens monitored by a monoclonal antibody capture enzyme-linked immunosorbent assay.
Chen PN; Liu HJ; Shien JH; Lee LH
Res Vet Sci; 2004 Jun; 76(3):219-25. PubMed ID: 15046956
[TBL] [Abstract][Full Text] [Related]
56. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
[TBL] [Abstract][Full Text] [Related]
57. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
58. Cell substrate for killed poliovaccine production.
Beale AJ
Dev Biol Stand; 1981; 47():19-23. PubMed ID: 6262147
[TBL] [Abstract][Full Text] [Related]
59. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency.
Maas R; van Diepen M; Komen M; Oei H; Claassen I
Dev Biol (Basel); 2002; 111():313-8. PubMed ID: 12678255
[TBL] [Abstract][Full Text] [Related]
60. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
